Carregant...
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...
Guardat en:
| Publicat a: | J Kidney Cancer VHL |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Codon Publications
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5345528/ https://ncbi.nlm.nih.gov/pubmed/28326248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2014.10 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|